Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03178552 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT03178552 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,000 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03178552, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Alectinib
Study Locations (20)
Other
- Fundación CENIT para la Investigación en Neurociencias - Buenos Aires
- Hospital Italiano - Buenos Aires
- Hospital Britanico de Buenos Aires - Ciudad Autonoma Buenos Aires
- UZ Brussel - Brussels
- Cliniques Universitaires St-Luc - Brussels
Florida
- SCRI Florida Cancer Specialists South - Fort Myers
- Florida Cancer Specialist, North Region - St. Petersburg
New York
- Weill Cornell Medical College-New York Presbyterian Hospital - New York
- Montefiore Medical Center - The Bronx
California
- UC Davis - Sacramento
Colorado
- Rocky Mountain Cancer Center - Denver
Kentucky
- University of Kentucky - Lexington
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03178552
The ClinicalTrials.gov registry entry for NCT03178552 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03178552 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03178552 about?
NCT03178552 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)". This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutat...
What is the current status of trial NCT03178552?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2017-09-22. Estimated completion is 2026-10-31.
What conditions does trial NCT03178552 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03178552?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Alectinib (DRUG).
Who is sponsoring clinical trial NCT03178552?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03178552 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.